Top

Published in:

01-12-2007 | Letter

Comment on: Gale EAM (2007) To boldly go—or to go too boldly? The accelerator hypothesis revisited. Diabetologia 50:1571–1575—a reply to the editor

Author: T. J. Wilkin

Published in: Diabetologia | Issue 12/2007

Excerpt

To the Editor: The Editor’s erudite commentary [1] on the accelerator hypothesis and its impact on the classification of diabetes [2] points to where the hypothesis may be vulnerable, offers the opportunity for adjustment and sets an intellectual standard by which the hypothesis will stand or fall. The hypothesis is based on the construct of tempo [3], and envisages a hierarchy of genotypes that respond to insulin resistance with corresponding rates of beta cell loss. Accordingly, a rise in insulin resistance across a population would predict a leftward shift, resulting in younger age at onset and an increase in incidence, both fundamental tenets of the hypothesis because they spell acceleration. …

Gale EAM (2007) To boldly go—or to go too boldly? The accelerator hypothesis revisited. Diabetologia 50:1571–1575PubMedCrossRef

Wilkin TJ (2007) Changing perspectives in diabetes: their impact on its classification. Diabetologia 50:1587–1592PubMedCrossRef

Wilkin TJ (2001) The accelerator hypothesis: weight gain as the missing link between type I and type ll diabetes. Diabetologia 44:914–922PubMedCrossRef

Wilkin TJ (2007) The accelerator hypothesis cannot be tested using the type 2 diabetes gene, TCF7L2. Diabetologia 50:1780PubMedCrossRef

Field SF, Howson JMM, Smyth DJ, Walker NM, Dunger DB, Todd JA (2007) Analysis of the type 2 diabetes gene, TCF7L2, in 13,795 type 1 diabetes cases and control subjects. Diabetologia 50:212–213PubMedCrossRef

Field SF, Howson JMM, Walker NM, Dunger DB, Todd JA (2007) Analysis of the obesity gene FTO in 14,803 type 1 diabetes cases and controls. Diabetologia DOI 10.1007/s00125-007-0767-0

Hawa MI, Bonfanti R, Valeri C, Delli Castelli M, Beyan H, Leslie RD (2005) No evidence for genetically determined alteration in insulin secretion or sensitivity predisposing to type 1 diabetes: a study of identical twins. Diabetes Care 28:1415–1418PubMedCrossRef

Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC (2004) Insulin resistance is a risk factor for progression to type 1 diabetes. Diabetologia 47:1661–1667PubMedCrossRef

Diabetes Prevention Trial–Type 1 Diabetes Study Group (2002) Effects of insulin on relatives of patients with type 1 diabetes. N Engl J Med 346:1658–1691CrossRef

10.

The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group (2002) A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 363:925–931

11.

Dabelea D, D’Agostino RB, Mayer-Davis EJ et al (2006) Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes. Diabetes Care 29:290–294PubMedCrossRef

12.

Wilkin TJ (2006) Testing the accelerator hypothesis: body size, beta-cell function, and age at onset of type 1 (autoimmune) diabetes: response to Dabelea et al. Diabetes Care 29:1462–1463 (author reply 1463–1464)PubMedCrossRef

13.

Knowler WC, Barrett-Connor E, Fowler SE et al.; Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403PubMedCrossRef

Title: Comment on: Gale EAM (2007) To boldly go—or to go too boldly? The accelerator hypothesis revisited. Diabetologia 50:1571–1575—a reply to the editor
Author: T. J. Wilkin
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 12/2007
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0829-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Comment on: Gale EAM (2007) To boldly go—or to go too boldly? The accelerator hypothesis revisited. Diabetologia 50:1571–1575—a reply to the editor

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 12/2007

Brothers of women with polycystic ovary syndrome are characterised by impaired glucose tolerance, reduced insulin sensitivity and related metabolic defects

Notch signalling suppresses apoptosis in adult human and mouse pancreatic islet cells

Associations between insulin resistance and TNF-α in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes

Lowering serum urate does not improve endothelial function in patients with type 2 diabetes

IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts

Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page